CCR9 KO cell line available to order. Free of charge wild type control provided.
MCF7
Human
Breast
Liquid
C C chemokine receptor D6, C-C chemokine receptor type 9, CC Chemokine receptor CCR10, CC-CKR-9, CCBP2, CCR9_HUMAN, CDw199, CDw199 antigen, CMKBR9, Chemokine (C C motif) receptor 9, Chemokine (C C motif) receptor 9, isoform CRA_a, Chemokine (C-C motif) receptor 9 isoform A, Chemokine (C-C motif) receptor 9 isoform B, Chemokine C C motif receptor 9, Chemokine C C receptor 10, Chemokine receptor CCR 9, Chemokine-binding protein D6, Cmkbr10, G-protein coupled receptor 28, GPR 28, GPR-9-6, OTTHUMP00000164653, OTTHUMP00000164654
CCR9 KO cell line available to order. Free of charge wild type control provided.
MCF7
Human
Breast
Liquid
Adenocarcinoma
CCR9
Knockout
CRISPR technology
EU: 1 US: 1
Adherent
Female
Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.
1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.
MEM + 10% FBS + 0.01 mg/ml bovine insulin
Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.
Dry Ice
-196°C
-196°C
Although we aim to provide customers with a homozygous clone, feasibility will be dependent on the biology of the protein. Should only heterozygous edits be achieved, you will be notified of the outcome and be asked to confirm whether the cell line is acceptable. All clones will be accompanied with DNA sequencing data, and the mutation description.
Recommended control: Human wild-type MCF7 cell line (Human wild-type MCF7 cell line ab288560). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.
This supplementary information is collated from multiple sources and compiled automatically.
CCR9 also known as CD199 is a chemokine receptor known for its role in guiding cell traffic. It is a G-protein-coupled receptor with a mass of approximately 43 kDa. CCR9 is mainly expressed on the surface of thymocytes T lymphocytes and some subsets of dendritic cells. Its presence is especially noted in the small intestine correlated with its role in the migration and function of immune cells in the gut. This receptor is important for the homing of these cells to the intestinal mucosa engaging specifically with its ligand CCL25.
CCR9 plays a significant role in the immune system particularly in the gut. It is part of chemokine receptor-ligand complexes that are integral to leukocyte trafficking. By interacting with CCL25 CCR9 facilitates the directed movement of immune cells across intestinal tissue impacting the immune surveillance and response within this environment. The receptor's expression pattern also suggests involvement in thymocyte development supporting the immune system's ability to generate a diverse repertoire of T cells.
CCR9 is an important component of the chemokine signaling pathway. It is intricately connected to G-protein signaling events triggering downstream effects that drive cell migration and adhesion. This pathway is important for the function and maintenance of mucosal immunity linking CCR9 with CCR7 and its role in guiding T cell migration to specific tissue sites. These pathways collectively support immune functionality and homeostasis underlining CCR9's significance in tissue-specific immunity.
CCR9 has associations with inflammatory disorders like Crohn's disease and ulcerative colitis. Inflammatory bowel disease (IBD) is marked by aberrant immune cell movement and function areas where CCR9 is particularly influential. The receptor's interaction with CCL25 is pivotal in these pathological conditions often being a therapeutic target to modulate immune cell trafficking in disease management. Additionally the altered expression of CCR9 may contribute to the progression of specific T-cell leukemias further emphasizing its clinical relevance.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com